[Translation] Phase 3 trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced, advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
比较接受LOXO-292治疗与接受卡博替尼或凡德他尼治疗的进展性、晚期、未经激酶抑制剂治疗、RET突变型MTC患者中的TFFS。a:比较接受LOXO-292治疗与接受卡博替尼或凡德他尼治疗的进展性、晚期、未经激酶抑制剂治疗、RET突变型MTC患者中所观察到的其他有效性指标(根据RECIST 1.1标准).b:评价LOXO-292与卡博替尼或凡德他尼相比的安全性和耐受性.c:比较LOXO-292与卡博替尼或凡德他尼的耐受性.
[Translation] To compare TFFS in patients with progressive, advanced, kinase inhibitor-naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib. a: Comparison of other measures of efficacy observed in patients with progressive, advanced, kinase inhibitor-naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib (according to RECIST 1.1 Criteria).b: To evaluate the safety and tolerability of LOXO-292 compared to cabozantinib or vandetanib.c: To compare the tolerability of LOXO-292 to cabozantinib or vandetanib .